Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
J.Molner ASOTSE:MOLNR -0.53%40 Return-on-Tangible-Equity is Negative Tangible Equity% as of Dec. 2025. GuruFocus rates OTSE:MOLNR with a GF Score™ of 40/100 and a GF Value™ of €19.62 (Fairly Valued). The stock has 7 warning signs investors should review. Among 896 Drug Manufacturers companies, J.Molner AS ranks better than 99.89% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. J.Molner AS's annualized net income for the quarter that ended in Dec. 2025 was €3.08 Mil. J.Molner AS's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €-2.25 Mil. Therefore, J.Molner AS's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was Negative Tangible Equity%.
The historical rank and industry rank for J.Molner AS's Return-on-Tangible-Equity or its related term are showing as below:
OTSE:MOLNR'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: Negative Tangible Equity
OTSE:MOLNR's Return-on-Tangible-Equity is ranked better than 99.89% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.59
vs OTSE:MOLNR: Negative Tangible Equity
J.Molner AS (OTSE:MOLNR) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
J.Molner AS Return-on-Tangible-Equity Related Terms
J.Molner AS Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for J.Molner AS's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OTSE:MOLNR vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
J.Molner AS Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where J.Molner AS's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of Negative Tangible Equity% mean?
J.Molner AS (OTSE:MOLNR) has a Return-on-Tangible-Equity of Negative Tangible Equity% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on J.Molner AS and its competitors. According to the industry distribution chart, J.Molner AS ranks #1 out of 896 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is J.Molner AS's Return-on-Tangible-Equity too high?
J.Molner AS's current Return-on-Tangible-Equity is Negative Tangible Equity%. Based on the distribution chart, J.Molner AS ranks #1 out of 896 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, J.Molner AS has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, J.Molner AS ranks #1 out of 896 companies for Return-on-Tangible-Equity. This places J.Molner AS in the top 0% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.59, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on J.Molner AS and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. J.Molner AS's current Return-on-Tangible-Equity is Negative Tangible Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.62, compared to a current price of €18.90 — trading 3.7% below its estimated fair value. The current Return-on-Tangible-Equity is Negative Tangible Equity%. J.Molner AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current Return-on-Tangible-Equity is Negative Tangible Equity% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?
Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued.
The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.62.
GuruFocus considers J.Molner AS to be Fairly Valued.
No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score
Get the complete analysis for OTSE:MOLNR
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTSE:MOLNR has been successfully added to your 
